debt_leverage_profile
-0.14x Total Debt / Equity (Negative equity)
High
SEC-XBRL
interest_rate_sensitivity
Low direct debt sensitivity; minimal long-term debt, but rising rates increase equity dilution cost as company relies on equity financing rounds
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
Single-source optical component suppliers in Asia (Taiwan/China) and specialized medical-grade fiber optic manufacturers concentrated in Germany
Inferred
Agent_Inference
international_expansion_readiness
Minimal international revenue; primary exposure is USD-denominated US market; foreign currency devaluation risk is negligible given domestic-only sales stage
Inferred
Agent_Inference
geographic_footprint
Predominantly US-based operations; no material international revenue markets; sovereign currency devaluation exposure effectively zero
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
Yes; proprietary LightTouch optical biopsy hardware relies on non-substitutable specialized photonics components from limited single-source suppliers
Inferred
Agent_Inference
business_model_type_primary
Cloud infrastructure termination would have minimal operational impact; company uses basic IT infrastructure, not cloud-dependent SaaS or data platform
Inferred
Agent_Inference
business_model_type_secondary
Medical device hardware/capital equipment model; cloud dependency is administrative only, not core to product delivery or revenue generation
Inferred
Agent_Inference
switching_cost_profile
No significant API coupling risk; product is a standalone FDA-regulated medical device without third-party API dependencies in core diagnostic function
Inferred
Agent_Inference
howey_test_risk_index
Low Howey Test risk; revenue model based on regulated medical device sales, not investment contracts or profit-sharing arrangements
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Low GDPR/CCPA exposure; company collects minimal personal data; clinical data handled by hospital partners under their own compliance frameworks
Inferred
Agent_Inference
antitrust_exposure_flag
Negligible antitrust risk; company holds small market share in cervical cancer diagnostics niche with no dominant market position
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
Approximately 0% recurring subscription revenue; nearly 100% transactional capital equipment and disposable probe sales; no multi-year contracts reported
Inferred
Agent_Inference
monetization_vector
Device capital sale plus recurring disposable cervical probe consumable per-procedure revenue; razor-and-blade model not yet scaled
Inferred
Agent_Inference
pricing_architecture
Pricing vulnerable to hospital budget scrutiny; device ASP ~$15,000-$20,000 with probe consumables; reimbursement coding uncertainty is key stress point
Inferred
Agent_Inference
pricing_power_rating
Low pricing power; dependent on third-party reimbursement rates set by CMS/payers; no demonstrated ability to raise prices independently
Inferred
Agent_Inference
target_gross_margin_bracket
74.4% Gross Margin (Premium (>60%))
High
SEC-XBRL
churn_vulnerability_index
No free-rider problem; device requires purchased disposable probes per use; however, low installed base creates adoption stagnation risk
Inferred
Agent_Inference
headcount_cost_structure
Revenue growth is headcount-sublinear for manufacturing but linear for sales force expansion; direct sales model requires proportional rep additions
Inferred
Agent_Inference
marginal_cost_of_growth
Marginal cost of growth is high; requires capital equipment placement, clinical training, and reimbursement navigation per new hospital customer
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; company has no franchise network
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC economics remain challenged; hospital sales cycles of 12-18 months and clinical validation requirements limit scalability
Inferred
Agent_Inference
network_effect_present
No meaningful network effects; medical device adoption driven by clinical outcomes data and reimbursement, not user network size
Inferred
Agent_Inference
asset_efficiency_ratio
-241.4% Return on Assets (Negative equity)
High
SEC-XBRL
recession_resistance_tier
Low recession resistance; cervical cancer screening device is a discretionary capital purchase for hospitals subject to budget cuts during downturns
Inferred
Agent_Inference
customer_segment_primary
OB/GYN clinics and hospital women's health departments; high customer concentration risk given small installed base of roughly dozens of units
Inferred
Agent_Inference
customer_segment_secondary
Colposcopy clinics and federally qualified health centers; secondary segment underdeveloped with no reported significant revenue concentration data
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
0.3% CapEx / Revenue (Low-CapEx Asset-Light)
High
SEC-XBRL
sec_cik
0000924515
High
SEC-EDGAR
ticker
GTHP
High
SEC-EDGAR